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ABSTRACT 40 
Background: The relationship between pathway delays and bladder cancer-specific survival 41 
is complex due to the influence of tumour- and patient-specific factors. 42 
 43 
Objective: To investigate the influence of tumour factors, patient factors, carcinogen 44 
exposure and pathway delays on the long-term outcome of urothelial bladder cancer (UBC). 45 
 46 
Design, Setting and Participants: A cohort of 1537 UBC patients were enrolled 1/1/1991-47 
30/6/1992 and followed-up for 17.7years. The period from onset of symptoms to first 48 
treatment (TURBT) was divided into 3 components of potential delay. 49 
 50 
Outcome Measurements and Statistical Analysis: Associations between patient factors, 51 
tumour factors and delay times were analysed using Pearson’s chi-squared test and Mann–52 
Whitney U-test. Survival was calculated from date of TURBT to date of death or censor date 53 
of 31/12/2010. Competing risks of death were assessed with the cumulative incidence 54 
function (CIF); comparisons of CIFs were performed using Gray’s test. 55 
 56 
Results: At censor, reliable data were available for 1478 patients, of which 75% had died. 57 
Females presented more commonly with muscle-invasive bladder cancer (MIBC) (30% vs. 58 
26%) and less frequently with pT1 disease (18% vs. 24%) (p=0.06), had a longer total delay 59 
time (median 120days vs. 106days, p=0.02), and those with MIBC had a significantly higher 60 
cumulative incidence of death due to UBC (80% vs. 67% at 17years, p<0.02). Cox regression 61 
Page | 4  
 
identified age, smoking status, and tumour stage, grade, and size as the most significant 62 
determinants of poor outcome. 63 
  64 
Limitations: We did not capture downstream delays associated with cystectomy or 65 
radiotherapy. 66 
 67 
Conclusions: Female patients present later than males, and our data suggest that delay in 68 
referral may be contributory. The relationship between gender, outcomes, delays and 69 
aetiology of UBC is complex.  70 
 71 
Patient Summary: We followed a large group of bladder cancer patients for over 17years. 72 
The relationship between pathway delays and survival is complex. However, female patients 73 
present later than male patients, and our data suggest that delay in referral from general 74 
practice may be contributory.75 
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INTRODUCTION 76 
Urothelial bladder cancer (UBC) is the fifth most common cancer in Western societies, 77 
accounting for 10,000, 69,000 and 180,000 new cases per year in the UK, USA and EU [1], 78 
respectively. The global incidence of the disease is rising reflecting patterns of cigarette 79 
smoking and occupational carcinogen exposure [2], the most common aetiological factors 80 
[1]. There has been little improvement in the outcome for UBC patients since the 1980s, 81 
reflecting complex diagnostic pathways and treatment regimens, and a lack of therapeutic 82 
advances [3]. Given these constraints, much attention has been paid to reducing delays in 83 
presentation [4], diagnosis and treatment [5].  84 
 85 
For UBC the relationship between time to diagnosis and treatment, and disease-specific 86 
survival is complex [6-9]; many tumours are indolent, for which delay in diagnosis does not 87 
alter survival [10], and outcomes from aggressive UBCs are multifactorial [6-9]. In addition 88 
to delays in healthcare pathways, disease biology (reflected by stage, grade and tumour 89 
characteristics [11;12]) and patient-specific factors are important. The latter reflect 90 
aetiological agent exposures (e.g. smoking is more common in males) [9;13;14], gender-91 
specific misdiagnoses (e.g. females are more likely to be incorrectly diagnosed with infection 92 
[15]) [1;16;17], and potential differences in the molecular pathogenesis of male and female 93 
UBC [18]. 94 
 95 
To obtain a clearer understanding of factors affecting outcomes in UBC, we have followed a 96 
large cohort of prospectively recruited patients since 1991 [9].  This population represents 97 
85% of new cases of UBC arising over an 18month period within the West Midlands region 98 
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of the UK [9]. Here we report long-term outcomes and investigate the influence of gender, 99 
carcinogen exposure and pathway delays in this cohort.  100 
101 
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PATIENTS AND METHODS 102 
Patients 103 
Patients newly-diagnosed with UBC within the West Midlands (UK) were prospectively 104 
recruited from 1st January 1991 through 30th June 1992 [9]. Data regarding exposures, dates 105 
of onset of symptoms, first referral by GP, first hospital appointment and first treatment 106 
(date of TURBT) were collected at recruitment. Data were checked to ensure that TNM 107 
classification correlated with histopathology and bimanual examination findings. 108 
Discrepancies were resolved by the investigators and the operating Consultant. All patients 109 
were notified to the West Midlands’ cancer registry, who provided death information at the 110 
censor date of 31st December 2010. Ethics committee approval was received prior to study 111 
opening. Ex-smoking was defined as abstinence for >12 months. Occupational exposure was 112 
identified by 3 assessors (>90% consensus) utilising IARC contemporary evidence to assign 113 
no risk, possible risk and definite risk of working in an occupation implicated in the 114 
pathogenesis of UBC (see Supplementary Table 1) [19]. 115 
 116 
Pathway measures 117 
Pathway times were defined as:  118 
 Time 1: date of onset of patient’s symptoms to date of GP’s first referral to 119 
secondary care; 120 
 Time 2: date of GP’s first referral to secondary care to date of first hospital 121 
attendance for urological assessment;  122 
 Time 3: date of first hospital attendance to date of first treatment by TURBT. 123 
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Hospital delay included the addition of Times 2 and 3, and Total delay was the summation of 124 
all three time periods. 125 
 126 
Statistical Methods 127 
All statistical analyses were performed using Stata 11.2 (StataCorp LP, College Station, 128 
Texas, USA) and R version 2.13.2 (The R Foundation for Statistical Computing, http://www.R-129 
project.org). Associations between patient and tumour features, with median delay times 130 
were analysed using Pearson’s chi-squared test for categorical data and the Mann–Whitney 131 
U-test for continuous data. Survival was calculated from the date of first TURBT to the date 132 
of death or censor date of 31st December 2010, using all-cause mortality. Survival curves for 133 
each stage (Ta, T1, T2-4) were constructed using the Kaplan-Meier method and outcomes 134 
between groups compared using the log-rank test. We estimated relative survival to 135 
calculate the crude probability of death in the general population compared to patients 136 
diagnosed with pTa tumours using the user written Stata command strs matched for age at 137 
diagnosis, sex and year of diagnosis [20]. The calculated probabilities were based upon the 138 
Ederer II method. Survival was compared in terms of demographic and tumour 139 
characteristics and delay times. A stratified survival analysis was used to test for differences 140 
within delay times adjusting for tumour stage and to test for smoking status adjusting for 141 
delay times. Cox-proportional hazards models using a complete case approach were applied 142 
to investigate the independent effect of age, sex, smoking status, haematuria, tumour stage, 143 
grade, type, size and number. We tested the proportional hazards assumption of the models 144 
by examining the Schoenfeld and scaled Schoenfeld residuals; in each test the proportional 145 
hazards assumption was met. In addition, we evaluated the fit of the models using Cox-Snell 146 
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residuals which confirmed the models to fit the data well. This formed a base model that 147 
was used to adjust the effects of each delay. Hazard ratios with 95% CI and P values are 148 
presented. 149 
To assess the competing risks of death, we first used a non-parametric test to assess the 150 
equality between groups by calculating the cumulative incidence function (CIF) as described 151 
by Scrucca et al. [21]. Comparison of specific CIFs was performed using Gray’s test [22]. See 152 
Supplementary Methods for further details.   153 
154 
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RESULTS 155 
Cohort description 156 
In total, 1537 patients were enrolled into the study and reliable long-term survival data 157 
were available on 1478 (96.2%) (Table 1). The cohort was typical for UBC, with a male to 158 
female ratio of 3:1 and a median age at diagnosis of 69 years for male (IQR 62-76) and 71 159 
years for female patients (IQR 64-78). Most patients were current or former cigarette 160 
smokers (973, 77%), and 330 (27%) patients were classified as having possible or definite 161 
exposure to occupational carcinogens. As detailed previously, patients were treated by 162 
contemporaneous standard practice (which did not include re-resection), and surveillance 163 
was carried out according to national guidelines [9]. At the censor date, the mean follow-up 164 
was 106 months (8.8 years, IQR 22.0-212.8 months) and 1109 patients (75%) had died. The 165 
cause of death was known for 983 patients (89% of deaths) (Table 2).  166 
 167 
Pathological features 168 
There was a significant association between tumour stage and death from UBC (P<0.005, 169 
Figure 1). Whilst most patients with MIBC died from the disease, the majority of patients 170 
with NMIBC died from other causes (Table 2); notably, >10% of patients originally 171 
presenting with pTa tumours, and >27% of patients originally presenting with pT1 tumours, 172 
subsequently died from UBC. 173 
 174 
Gender 175 
There was no difference in grade at presentation between the genders (p=0.16). However, 176 
females presented more commonly with MIBC (30% vs. 26% for males) and less frequently 177 
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with pT1 disease (18% vs. 24% for males) (p=0.06, Table 3). Females had a longer total delay 178 
time than males (median 120days vs. 106days, respectively, p=0.02) (Tables 3 and 4). The 179 
majority of this delay arose before hospital referral (Table 3); a significantly higher 180 
proportion of female patients with visible haematuria encountered a longer delay Time 1 181 
than equivalent male patients (p<0.05, Table 4).  182 
 183 
Female patients with MIBC had a significantly higher cumulative incidence of death from 184 
UBC than male patients at 17 years (80% vs. 67%, p<0.02). There was no difference in UBC 185 
mortality between the genders for pTa and pT1 tumours (14% vs. 15%, p=0.56 and 34% vs. 186 
38%, p=0.58, respectively) (Figure 2a), and for other causes of death. Female patients with 187 
grade 3 tumours had a significantly higher cumulative incidence of UBC death than males 188 
(73% vs. 58%, p=0.002), but no difference was seen for grade 1 and 2 (14% vs. 15%, p=0.65 189 
and 32% vs. 38% p=0.23, respectively) (Figure 2b). 190 
 191 
Cigarette Smoking 192 
At presentation, 77% of patients were current or previous smokers (Table 1). As observed in 193 
the general population at the time, more men smoked (84%) than women (55%, p<0.001, 194 
Table 4). Based on an age or date of stopping smoking obtained for all previous smokers, 195 
the median duration of smoking cessation was 16 years (mean 18.8 years). In univariate 196 
analysis there was a trend for cigarette smoking to be associated with increased cumulative 197 
incidence of death due to UBC, death from other cancers, and death from other causes, but 198 
none reached significance (Supplementary Figure 1a). 199 
 200 
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Occupational Carcinogen Exposure 201 
We identified that 27% of patients had worked in occupations linked with UBC, with higher 202 
exposure in males (31%) than females (14%, p<0.0001, Table 3). There was a trend for 203 
occupational exposure to be associated with increased cumulative incidence of death due to 204 
UBC and death due to other causes, but none reached significance (Supplementary Figure 205 
1b). 206 
 207 
Pathway delays 208 
The median time from initial onset of symptoms to GP referral was 14days (Time 1, IQR: 0-209 
61), from referral to hospital consultation was 28days (Time 2, IQR: 7-61), and from 210 
consultation to first treatment was 20days (Time 3, IQR: 0-50). Patient characteristics by 211 
delay times are shown in Table 4. Longer delays in Time 3 and Hospital Delay were 212 
associated with smaller tumour size (p<0.05 for both). A longer Total Delay was seen for 213 
females (120days vs. 106days, p<0.05) and non-smokers (118days vs. 105days, p<0.05) 214 
when compared to other patients.  215 
 216 
Analysis of survival by delay stratified for tumour stage demonstrated no impact 217 
(Supplementary Table 2), except for patients with MIBC for whom a shorter delay Time 3 218 
resulted in worse survival compared to those with longer delay (p<0.05).  219 
 220 
Predictors of Survival 221 
Univariate analysis identified histopathological criteria, gender, delays and smoking as 222 
factors associated with UBC outcomes. Since these parameters are not necessarily 223 
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independent, multivariate analysis was used to determine the impact of each feature. Cox 224 
regression of delay times adjusted by a base model of independent factors identified that 225 
age, smoking status, and tumour stage (MIBC), grade (3), and size (>2cm) were the most 226 
significant determinants of poor outcome from UBC (Supplementary Table 3). There was no 227 
significant influence of delay, gender or occupational exposure.  228 
 229 
230 
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DISCUSSION 231 
Here we report 17-year outcomes from newly-diagnosed cases of UBC within a large 232 
geographic region in the UK. We have updated an initial report [9], and now have most 233 
cases (75%) followed until death. We are thus able to examine the complex interaction 234 
between the tumour, patient gender, carcinogen exposures, pathway delays, and mortality. 235 
We identified in univariate and competing risks analysis that many of these factors were 236 
associated with disease-specific mortality. However, multivariate analysis identified age, 237 
smoking status, and tumour stage, grade, and size as the most significant determinants of 238 
poor outcome from UBC. Notably, there was no significant influence of delay, gender or 239 
occupational exposure. 240 
 241 
Comparison of CIFs demonstrated significant associations between female gender and 242 
higher cumulative incidence of death from grade 3 disease and MIBC, concurring with 243 
previous reports of worse outcomes for females with UBC [1;16;17;23;24]. Furthermore, 244 
there was a trend for female patients to present more commonly with MIBC than male 245 
patients. Importantly, female patients experienced a significantly longer Total Delay than 246 
male patients. The majority of this delay occurred in Time 1, before referral for investigation 247 
in secondary care was implemented by GPs; a significantly higher proportion of female 248 
patients with visible haematuria encountered longer delays in Time 1 than equivalent male 249 
patients. These data support observations of repeated community-based treatments for 250 
suspected urinary infection in symptomatic females [25;26]. As reported by Hollenbeck et 251 
al. [7], there were no significant differences in delays between the genders once patients 252 
were within secondary care.  253 
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Female patients with MIBC had a significantly higher cumulative incidence of death from 254 
UBC than male patients; it is unlikely that differential utilisation of radiotherapy or 255 
cystectomy between the genders would cause this effect, but there is limited evidence to 256 
suggest that female patients have worse outcomes from radiotherapy compared to males 257 
[27]. However, such effects were not large enough for gender to be an independent 258 
prognostic factor in multivariate analysis when adjusted for pathway delays. 259 
 260 
It is a commonly-held belief that more rapid cancer diagnosis and treatment leads to better 261 
outcomes, and to suggest otherwise is counterintuitive [5;6]. However, the relationship 262 
between delay and survival in UBC is complex [8;9], with no direct linear relationship with 263 
any components of delay [6;9]. In the long-term follow-up of this cohort, we have confirmed 264 
this complex relationship, as noted by others [6;8;9]: no delay category had a significant 265 
influence on survival, except for patients with MIBC for whom a shorter Delay 3 was 266 
detrimental. This may represent an anomaly, and there is no clear explanation from our 267 
data, but it is feasible that patients with MIBCs with concerning features (e.g. ongoing 268 
bleeding) or comorbidities were selected for expedited treatment [9], subsequently 269 
succumbing more rapidly as a result of those features or comorbidities. This was also 270 
postulated by Liedberg, who demonstrated that a long treatment delay had no influence on 271 
survival following cystectomy [8]. Seemingly, once in secondary care, clinicians are good at 272 
selecting the highest risk patients and treating them rapidly [9]. Similarly, Nielsen 273 
demonstrated that delay from TURBT to radical cystectomy was not independently 274 
associated with stage progression or decreased recurrence-free or disease-specific survival 275 
[28]. Likewise, for UBC patients treated by radiotherapy, there is no significant influence of 276 
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treatment delay on survival [29]. However, Hollenbeck investigated delay and survival in 277 
29,826 patients with UBC and demonstrated that longer delays from presentation to 278 
diagnosis were associated with increased risk of bladder cancer-specific mortality [7], a 279 
finding also demonstrated by Gore when assessing the interval between TURBT and 280 
cystectomy [30]. 281 
 282 
Many patient-related factors analysed here are not independent, e.g. males are more likely 283 
to smoke, to have occupational carcinogen exposure, and to be more rapidly referred for 284 
the investigation of haematuria [15]. Females are more likely to be non-smokers, are 285 
typically exposed to different occupational carcinogens, and are slower to be referred for 286 
investigation of haematuria or lower urinary tract symptoms [15;25;26]. In multivariate 287 
analysis, we identified that only tumour stage, grade and size, and patient age and smoking 288 
exposure were predictors of outcome when adjusted for pathway delays. These reinforce 289 
observations from RCTs of bladder cancer treatment, and suggest that gender-related 290 
disparities arise at least partly from a disease stage/grade migration due to diagnostic delay.  291 
 292 
A major limitation of this study is a lack of delay data ‘downstream’ from TURBT. However, 293 
the classification and interpretation of such data could be challenging (e.g. classifying the 294 
time to definitive treatment of MIBC in the setting of chemoradiotherapy or neoadjuvant 295 
chemotherapy/cystectomy), whereas TURBT remains the first intervention for all cases of 296 
UBC [11;12]. It could also be suggested that our outcome data are not applicable to modern 297 
practice (although outcomes from UBC have remained unchanged for over 30 years [3]), for 298 
example, there appear to be high rates of UBC-specific death for patients with Ta and T1 299 
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tumours; in 1991 these patients may have been understaged and undertreated in an era 300 
when re-TUR was  rare and the utilisation of intravesical therapies was uncommon. 301 
Furthermore, disease surveillance was according to national guidelines and may have 302 
limited generalisability for other healthcare systems. Given the nature of multicentre cohort 303 
studies, there was also likely to be heterogeneity in both treatment and surveillance 304 
strategies between participating units. Finally, the gathering of more comprehensive 305 
smoking and occupation data would have been more illuminating than the limited 306 
categorical data presented here.  The strengths of this study include its prospective nature, 307 
its mature and long-term follow-up, and the completeness of data from a large cohort.  308 
 309 
 310 
CONCLUSIONS 311 
Our data demonstrate a stage migration to MIBC in female patients at presentation. The 312 
relationships between gender, outcomes, delays and aetiology of UBC are complex. Female 313 
patients experience a significantly longer Total Delay than male patients, the majority of 314 
which results from a delay in referral from general practice to secondary care/urological 315 
assessment, and may contribute to stage migration. GPs should be particularly vigilant 316 
regarding symptoms that are associated with UBC, and especially in female patients; visible 317 
haematuria always requires urgent referral to secondary care for urological assessment.  318 
 319 
320 
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LEGENDS FOR TABLES AND FIGURES 321 
 322 
Table 1: Overall patient and tumour characteristics (where recorded). 323 
 324 
Table 2: Certified causes of death by tumour stage in the 983 patients where both tumour 325 
stage and cause of death were known.  326 
 327 
Table 3: Gender-specific characteristics of patients in the cohort. 328 
  329 
Table 4: Patient characteristics by delay times (in days), n (%). VH=visible hameaturia; 330 
NVH=non-visible haematuria.  331 
 332 
Figure 1: Survival by tumour stage and estimated survival for the general population. 333 
 334 
Figure 2a: Cumulative incidence of death due to bladder cancer, other cancer and other 335 
causes by gender and tumour stage (solid lines=male patients, dashed lines=female 336 
patients). 337 
 338 
Figure 2b: Cumulative incidence of death due to bladder cancer, other cancer and other 339 
causes by gender and tumour grade (solid lines=male patients, dashed lines=female 340 
patients). 341 
 342 
 343 
344 
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Table 1: Overall patient and tumour characteristics (where recorded). 345 
Variable Number (%) 
Gender (1478 responses, 100%)  
Male 1097 (74) 
Female 381 (26) 
 
Haematuria at presentation (1171 responses, 79%)  
Visible 1021 (87) 
Non-visible 67 (6) 
None 83 (7) 
 
Age, years (1478 responses, 100%)  
<60 315 (21) 
61-70 478 (32) 
71-80 495 (33) 
>80 190 (13) 
 
Smoking history (1260 responses, 85%)  
Current smoker 330 (26) 
Previous smoker 643 (51) 
Never smoked 287 (23) 
 
Occupational exposure (1240 responses, 84%)  
Known or suspected increased relative risk 330 (27) 
No increased relative risk 910 (73) 
 
Tumour type (1404 responses, 95%)  
Papillary 903 (64) 
Solid 246 (18) 
Mixed 255 (18) 
 
Tumour number (1392 responses, 94%)  
Single 1042 (75) 
2 or more 350 (25) 
 
Tumour size, cm (1366 responses, 92%)  
≤2 552 (40) 
>2 814 (60) 
 
Tumour stage (1300 responses, 88%)  
pTa 658 (51) 
pT1 291 (22) 
T2-T4 351 (27) 
 
Grade (1347 responses, 91%)  
Well (G1) 475 (35) 
Moderate (G2) 513 (38) 
Poor and anaplastic (G3) 359 (27) 
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Table 2: Certified causes of death by tumour stage in the 983 patients where both tumour stage and cause of death were known.  346 
Cause  pTa (%)*   pT1 (%)* T2-T4 (%)* Total 
  Well (G1) 
Moderate 
(G2) 
Poor and 
anaplastic 
(G3) 
Unknown All grades 
 Well 
(G1) 
Moderate 
(G2) 
Poor and 
anaplastic 
(G3) 
Unknown All grades All grades   
Bladder Cancer 31 (12) 30 (19) 5 (36) 1 (09) 67 (15)  11 (38) 39 (34) 24 (35) 5 (42) 79 (35) 219 (69) 365 
Other Cancer 65 (25) 31 (20) 2 (14) 2 (18) 100 (23)  5 (17) 12 (11) 10 (14) 2 (17) 29 (13) 24 (8) 153 
Other Causes 165 (63) 94 (61) 7 (50) 8 (73) 274 (62)  13 (45) 63 (55) 35 (51) 5 (42) 116 (52) 75 (24) 465 
Total 261 155 14 11 441  29 114 69 12 224 318 983 
*Rounded proportions may 
sum to more than 100% 
  
 
 
 
   
 
    347 
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Table 3: Gender-specific characteristics of patients in the cohort.  
 Males Females p 
Proportions 74% 26% <0.001 
    Haematuria at presentation    
Visible 87% 89% 0.673 
Non-visible 6% 5%  
None 7% 6%  
    
Grade    
G1 34% 39% 0.157 
G2 39% 35%  
G3 27% 26%  
    
Stage    
Ta 50% 52% 0.060 
T1 24% 18%  
T2-4 26% 30%  
    
Median Delay Time 1 14 23 0.101 
Delay 1 ≤14 days 51% 46%  
Delay 1 >14 days 49% 54%  
    
Median Delay Time 2 27 29 0.498 
Delay 2 ≤28 days 52% 50%  
Delay 2 >28 days 48% 50%  
    
Median Delay Time 3 22 18 0.152 
Delay 3 ≤20 days 48% 52%  
Delay 3 >20 days 52% 48%  
    
Median Hospital Delay 68 68 0.848 
Hospital Delay ≤68 days 51%  51%   
Hospital Delay >68 days 49% 49%  
    
Median Total Delay 106 120 0.024 
Total Delay ≤110 days 52% 45%  
Total Delay >110 days 48% 55%  
    
History of smoking 84% 55% <0.001 
    
History of occupational 
exposure 31% 14% <0.001 
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Table 4: Patient characteristics by delay times (in days), n (%).  
   
Time 1: Initial symptom 
to GP referral 
Time 2: GP referral to 
first consultation 
Time 3: Consultation to 
first Treatment Hospital Delay  Total Delay  
Factor Grouping N ≤14 >14 ≤28 >28 ≤20 >20 ≤68 >68 ≤110 >110 
Median age, years  70 69 69 70 70 69 70 69 69 70 
IQR   62-77 61-76 61-76 62-77 62-77 62-76 62-76 62-76 62-76 62-76 
             Sex Male 1097 548 (76) 523 (72) 553 (75) 518 (73) 511 (73) 560 (76) 549 (74) 525 (74) 558 (77)* 513 (72)* 
 Female 381 171 (24) 199 (28) 184 (25) 187 (27) 193 (27) 178 (24) 188 (26) 184 (26) 168 (23) 203 (28) 
             Tumour stage pTa 658 340 (54) 314 (48) 345 (52) 309 (50) 312 (51) 342 (51) 321 (49) 333 (52) 320 (50) 334 (52) 
 pT1 291 140 (22) 149 (23) 140 (21) 149 (24) 131 (21) 158 (24) 148 (23) 142 (22) 146 (23) 143 (22) 
 T2-T4 351 154 (24) 186 (29) 176 (27) 164 (26) 168 (27) 172 (26) 181 (28) 161 (25) 179 (28) 161 (25) 
             Tumour size, cm ≤2 552 286 (42) 259 (38) 272 (39) 274 (41) 244 (37) 302 (43) 247 (36) 301 (45) 259 (38) 287 (42) 
 >2 814 388 (58) 419 (62) 417 (61) 390 (59) 412 (63)* 395 (57)* 439 (64)* 370 (55)* 417 (62) 390 (58) 
             Presenting with 
haematuria VH (M) 755 301 (78)* 445 (72)* 452 (75) 149 (73) 259 (73) 487 (75) 405 (73) 343 (75) 390 (76) 356 (72) 
 VH (F) 266 86 (22) 174 (28) 149 (25) 111 (27) 98 (27) 162 (25) 148 (27) 113 (25) 124 (24) 136 (28) 
             
 NVH (M) 52 26 (79) 25 (76) 22 (76) 29 (78) 16 (76) 35 (78) 26 (76) 25 (78) 23 (74) 28 (80) 
 NVH (F) 15 7 (21) 8 (24) 7 (24) 8 (22) 5 (24) 10 (22) 8 (24) 7 (22) 8 (26) 7 (20) 
             
 None (M) 64 28 (82) 35 (73) 34 (69) 29 (88) 28 (65) 35 (90) 33 (73) 31 (82) 29 (74) 34 (79) 
 None (F) 19 6 (18) 13 (27) 15 (31) 4 (12) 15 (35)* 4 (10)* 12 (27) 7 (18) 10 (26) 9 (21) 
             Smoking Never 287 133 (21) 147 (24) 142 (22) 138 (23) 140 (23) 140 (22) 138 (22) 142 (23) 126 (20) 154 (25) 
  Ever 973 486 (79) 471 (76) 490 (78) 467 (77) 459 (77) 498 (78) 492 (78) 467 (77) 500 (80)* 457 (75)* 
*P<0.05 
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Figure 1: Survival by tumour stage and estimated survival for the general population. 
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Figure 2a: Cumulative incidence of death due to bladder cancer, other cancer and other 
causes by gender and tumour stage (solid lines=male patients, dashed lines=female 
patients). 
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Figure 2b: Cumulative incidence of death due to bladder cancer, other cancer and other 
causes by gender and tumour grade (solid lines=male patients, dashed lines=female 
patients). 
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SUPPLEMENTARY METHODS 
To assess the competing risks of death in our cohort, we first used a non-parametric test to 
assess the equality between groups by calculating the cumulative incidence function (CIF) as 
described by Scrucca et al. [1]. Comparison of specific CIFs was performed using Gray’s test 
[2]. We then extended our analysis to investigate the effects of other covariates (stage at 
diagnosis, tumour grade, gender, smoking status, occupational exposure risk and age group 
at diagnosis), present in our data on the CIF.  We constructed flexible parametric models 
using the user written Stata command stpm2 in order to calculate the cause-specific hazard 
for each cause and for each covariate of interest [3]. Gender and cause of death were 
modeled as time-varying covariates. We used information from the Akaike Information 
Criterion (AIC) and Bayesian Information Criterion (BIC) for model selection. Post-estimation 
we applied the user written stpm2cif command [4], so that the cumulative incidence 
function for each model of interest could be derived and graphed.  
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LEGENDS 
 
Supplementary Table 1: Occupations with known or suspected exposure to urothelial 
carcinogens, and chemicals implicated in urothelial carcinogenesis. These data were utilised 
by the assessors to assign risk of occupational exposure.  
 
Supplementary Table 2: Survival by delay times stratified for tumour stage.  
 
Supplementary Table 3: Cox regression of delay times adjusted by a base model of 
independent factors. 
 
Supplementary Figure 1a: Cumulative incidence of death due to bladder cancer, other 
cancer and other causes by smoking status (blue line=non-smoker, red line=current or ex-
smoker). 
 
Supplementary Figure 1b: Cumulative incidence of death due to bladder cancer, other 
cancer and other causes by risk of occupational exposure to bladder carcinogens (blue 
line=known or suspected risk of occupational exposure, red line=no increased risk of 
occupational exposure). 
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Supplementary Table 1: Occupations and carcinogens associated with urothelial carcinogenesis. 
Occupations with exposure to urothelial carcinogens Occupations with suspicion of an excess of bladder cancer Implicated chemicals 
Manufacture of rubber & rubber products Leather working 1-Naphthylamine 
Cable manufacturing industry Manufacture and use of paint 2-Naphthylamine 
Manufacture of dyestuffs Plastics industry 3,3'-Dicholorbenzidine 
Manufacture of organic chemicals Medical and nursing 3,3'-Dicholorbenzidine hydrochloride 
Gasworks, coke oven and iron foundry working Textile printing and dyeing 3,3'-Dimethoxybenzidine (o-Dianisidine) 
Rodent extermination Hairdressing 3,3'-Dimethylbenzidine (o-Tolidine) 
Sewage works Aluminium refining and smelting 4,4'-Methylene bis (2-Chloroaniline) 
Manufacture of firelighters/patent fuels Security printing 4,4'-Methylenedianiline (MDA) 
Laboratory work Mechanics and land transport working 4-Aminobiphenyl 
 
Machine turning 4-Chloro-o-toluidine (4-COT) 
  
Aniline 
  
Auramine 
  
Benzidine 
  
Benzidine dihydrochloride 
  
Benzidine hydrochloride 
  
Benzidine sulphate 
  
Magenta 
  
Phenyl 1-naphthylamine 
  
Phenyl b-naphthylamine 
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Supplementary Table 2: Survival by delay times stratified for tumour stage.  
     Median [95% CI] 
survival, years 
Surviving at years 
DELAY, N DAYS N Dead (N) %Alive O/E 1 3 5 10 
Time 1 (P=0.09)          
≤14 719 524 27.1% 0.97 7.8 [6.7,8.7] 86% 70% 61% 42% 
>14 722 554 23.3% 1.03 6.4 [5.6,7.5] 83% 67% 58% 39% 
Time 1 by tumour stage (P=<0.001)         
pTa           
≤14 340 220 35.3% 0.86 11.8 [9.5,13.4] 97% 87% 78% 55% 
>14 314 212 32.5% 0.90 10.8 [9.1,12.6] 96% 86% 75% 52% 
pT1           
≤14 140 102 27.1% 0.97 8.0 [6.1,10.4] 90% 76% 65% 42% 
>14 149 120 19.5% 1.08 5.7 [4.8,9.3] 88% 69% 58% 40% 
T2-T4           
≤14 154 140 9.1% 1.21 1.3 [1.0,1.7] 58% 31% 23% 15% 
>14 186 166 10.8% 1.19 1.3 [1.0,1.6] 59% 33% 25% 17% 
 
Time 2 (P=0.09)          
≤28 737 565 23.3% 1.03 6.2 [5.4,7.4] 83% 66% 57% 38% 
>28 705 513 27.2% 0.97 8.2 [7.0,9.0] 86% 71% 62% 43% 
Time 2 by tumour stage (P=<0.001)         
pTa           
≤28 345 238 31.0% 0.92 9.6 [8.6,11.5] 97% 85% 75% 49% 
>28 309 194 37.2% 0.84 12.9 [11.1,15.1] 96% 88% 79% 59% 
pT1           
≤28 140 109 22.1% 1.04 6.2 [4.4,10.0] 87% 70% 57% 42% 
>28 149 113 24.2% 1.01 7.8 [5.8,9.3] 91% 75% 65% 40% 
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T2-T4           
≤28 176 160 9.1% 1.21 1.1 [0.9,1.5] 55% 30% 21% 14% 
>28 164 146 11.0% 1.19 1.4 [1.1,2.1] 63% 34% 27% 18% 
 
Time 3 (P=0.45)          
≤20 704 520 26.1% 0.99 6.8 [5.5,8.1] 82% 66% 56% 39% 
>20 738 558 24.4% 1.01 7.5 [6.4,8.4] 87% 71% 62% 42% 
Time 3 by tumour stage (P=<0.001)         
pTa           
≤20 312 208 33.3% 0.89 10.1 [9.0,12.8] 95% 84% 73% 51% 
>20 342 224 34.5% 0.88 12.1 [10.0,13.4] 98% 89% 80% 56% 
pT1           
≤20 131 90 31.3% 0.92 8.8 [5.8,11.4] 90% 76% 63% 47% 
>20 158 132 16.5% 1.12 6.2 [5.0,8.2] 88% 70% 59% 35% 
T2-T4           
≤20 168 155 7.7% 1.23 1.0 [0.8,1.2] 53% 26% 18% 12% 
>20 172 151 12.2% 1.17 1.8 [1.3,2.4] 65% 38% 30% 20% 
 
Hospital Delay (P=0.30)          
≤68 737 560 24.0% 1.02 6.1 [5.4,7.4] 82% 65% 56% 37% 
>68 709 522 26.4% 0.98 8.1 [6.8,8.9] 87% 72% 62% 43% 
Hospital Delay by tumour stage (P=<0.001)        
pTa           
≤68 321 221 31.2% 0.92 9.6 [8.4,11.6] 96% 84% 74% 49% 
>68 333 211 36.6% 0.85 12.9 [11.1,14.1] 97% 89% 79% 58% 
pT1           
≤68 148 112 24.3% 1.01 7.8 [5.0,10.0] 87% 72% 59% 43% 
>68 142 111 21.8% 1.04 7.0 [5.6,8.6] 90% 73% 63% 39% 
T2-T4           
≤68 181 160 11.6% 1.18 1.1 [0.9,1.3] 55% 30% 23% 17% 
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>68 161 148 8.1% 1.23 1.7 [1.2,2.1] 64% 34% 26% 16% 
 
Total Delay (P=0.26)          
≤110 726 552 24.0% 1.02 6.9 [5.6,7.9] 83% 66% 58% 39% 
>110 716 526 26.5% 0.98 7.4 [6.4,8.6] 86% 71% 60% 41% 
Total Delay by tumour stage (P=<0.001)        
pTa           
≤110 320 217 32.2% 0.91 10.5 [9.0,12.3] 96% 86% 76% 52% 
>110 334 215 35.6% 0.86 12.5 [9.9,14.4] 96% 87% 78% 55% 
pT1           
≤110 146 112 23.3% 1.03 8.4 [6.2,10.5] 88% 74% 66% 46% 
>110 143 110 23.1% 1.03 5.7 [4.4,8.2] 90% 71% 57% 36% 
T2-T4           
≤110 179 160 10.6% 1.19 1.1 [0.8,1.4] 54% 30% 22% 16% 
>110 161 146 9.3% 1.21 1.6 [1.2,2.1] 64% 34% 26% 16% 
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Supplementary Table 3: Cox regression of delay times adjusted by a base model of independent factors. 
Factor Grouping Coefficient z P Hazard ratio (95% CI) 
Time 1 adjusted by base model (n=1001)     
Time 1 (≤14, >14 days) 0.10 1.34 0.18 1.11 (0.95,1.28) 
Age (Continous) 0.06 13.98 <0.001 1.06 (1.05,1.07) 
Tumour type      
 (Papilliary)    1 (1,1) 
 (Mixed) 0.24 1.67 0.09 1.27 (0.96,1.67) 
 (Solid) 0.13 1.11 0.27 1.14 (0.91,1.43) 
Tumour stage      
 (pTa)    1 (1,1) 
 (pT1) 0.10 0.95 0.34 1.11 (0.90,1.36) 
 (T2-T4) 0.50 3.43 <0.001 1.65 (1.24,2.20) 
Smoking (Never, ever) 0.36 3.72 <0.001 1.44 (1.19,1.74) 
Occupational exposure (No increased risk, known or suspect risk) 0.06 0.70 0.48 1.06 (0.90,1.26) 
Sex (Female, Male) 0.02 0.16 0.87 1.02 (0.84,1.22) 
Tumour grade      
 (Well differentiated)    1 (1,1) 
 (Moderately differentiated) 0.02 0.23 0.82 1.02 (0.85,1.23) 
 (Poorly differentiated) 0.31 2.26 0.02 1.36 (1.04,1.77) 
Tumour size (cm) (≤2, >2) 0.15 1.90 0.06 1.17 (0.99,1.36) 
Time 2 adjusted by base model (n=1001)     
Time 2 (≤28, >28 days) -0.11 -1.44 0.15 0.90 (0.78,1.04) 
Age (Continous) 0.06 13.89 <0.001 1.06 (1.05,1.07) 
Tumour type      
 (Papilliary)    1 (1,1) 
 (Mixed) 0.24 1.72 0.09 1.27 (0.97,1.68) 
 (Solid) 0.13 1.11 0.27 1.14 (0.90,1.43) 
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Tumour stage      
 (pTa)    1 (1,1) 
 (pT1) 0.11 1.03 0.31 1.11 (0.91,1.37) 
 (T2-T4) 0.52 3.58 <0.001 1.69 (1.27,2.24) 
Smoking (Never, ever) 0.36 3.69 <0.001 1.44 (1.19,1.74) 
Occupational exposure (No increased risk, known or suspect risk) 0.05 0.58 0.56 1.05 (0.89,1.24) 
Sex (Female, Male) 0.01 0.10 0.92 1.01 (0.84,1.21) 
Tumour grade      
 (Well differentiated)    1 (1,1) 
 (Moderately differentiated) 0.02 0.22 0.82 1.02 (0.85,1.23) 
 (Poorly differentiated) 0.30 2.24 0.03 1.35 (1.04,1.76) 
Tumour size (cm) (≤2, >2) 0.15 1.89 0.06 1.16 (0.99,1.36) 
Time 3 adjusted by base model (n=1001)     
Time 3 (≤20, >20 days) -0.09 -1.15 0.25 0.92 (0.79,1.06) 
Age (Continous) 0.06 13.91 <0.001 1.06 (1.05,1.07) 
Tumour type      
 (Papilliary)    1 (1,1) 
 (Mixed) 0.24 1.71 0.09 1.27 (0.96,1.68) 
 (Solid) 0.13 1.11 0.27 1.14 (0.91,1.43) 
Tumour stage      
 (pTa)    1 (1,1) 
 (pT1) 0.10 1.00 0.32 1.11 (0.90,1.36) 
 (T2-T4) 0.51 3.50 <0.001 1.66 (1.25,2.21) 
Smoking (Never, ever) 0.37 3.73 <0.001 1.44 (1.19,1.75) 
Occupational exposure (No increased risk, known or suspect risk) 0.06 0.69 0.49 1.06 (0.90,1.25) 
Sex (Female, Male) 0.01 0.09 0.93 1.01 (0.84,1.21) 
Tumour grade      
 (Well differentiated)    1 (1,1) 
 (Moderately differentiated) 0.01 0.13 0.89 1.01 (0.84,1.22) 
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 (Poorly differentiated) 0.32 2.35 0.02 1.37 (1.05,1.79) 
Tumour size (cm) (≤2, >2) 0.15 1.87 0.06 1.16 (0.99,1.36) 
Hospital delay adjusted by base model (n=1003)     
Hospital delay (≤68, >68 days) -0.06 -0.84 0.40 0.94 (0.81,1.09) 
Age (Continous) 0.06 13.95 <0.001 1.06 (1.05,1.07) 
Tumour type      
 (Papilliary)    1 (1,1) 
 (Mixed) 0.24 1.68 0.09 1.27 (0.96,1.67) 
 (Solid) 0.13 1.09 0.28 1.14 (0.90,1.43) 
Tumour stage      
 (pTa)    1 (1,1) 
 (pT1) 0.11 1.04 0.3 1.12 (0.91,1.37) 
 (T2-T4) 0.51 3.50 <0.001 1.66 (1.25,2.21) 
Smoking (Never, ever) 0.37 3.73 <0.001 1.44 (1.19,1.75) 
Occupational exposure (No increased risk, known or suspect risk) 0.06 0.66 0.51 1.06 (0.89,1.25) 
Sex (Female, Male) 0.01 0.14 0.89 1.01 (0.84,1.22) 
Tumour grade      
 (Well differentiated)    1 (1,1) 
 (Moderately differentiated) 0.02 0.21 0.83 1.02 (0.85,1.23) 
 (Poorly differentiated) 0.32 2.35 0.02 1.37 (1.05,1.79) 
Tumour size (cm) (≤2, >2) 0.14 1.77 0.08 1.15 (0.98,1.35) 
Total delay adjusted by base model (n=1001)     
Total delay (≤110, >110 days) 0.01 0.18 0.86 1.01 (0.88,1.17) 
Age (Continous) 0.06 13.92 <0.001 1.06 (1.05,1.07) 
Tumour type      
 (Papilliary)    1 (1,1) 
 (Mixed) 0.24 1.70 0.09 1.27 (0.96,1.68) 
 (Solid) 0.13 1.09 0.28 1.14 (0.90,1.43) 
Tumour stage      
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 (pTa)   <0.001 1 (1,1) 
 (pT1) 0.11 1.02 0.31 1.11 (0.91,1.37) 
 (T2-T4) 0.51 3.46 <0.001 1.66 (1.25,2.21) 
Smoking (Never, ever) 0.37 3.73 <0.001 1.44 (1.19,1.75) 
Occupational exposure (No increased risk, known or suspect risk) 0.06 0.70 0.48 1.06 (0.90,1.26) 
Sex (Female, Male) 0.01 0.12 0.91 1.01 (0.84,1.22) 
Tumour grade      
 (Well differentiated)    1 (1,1) 
 (Moderately differentiated) 0.02 0.19 0.85 1.02 (0.85,1.23) 
 (Poorly differentiated) 0.31 2.29 0.02 1.36 (1.05,1.78) 
Tumour size (cm) (≤2, >2) 0.16 1.92 0.05 1.17 (1.00,1.37) 
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Supplementary Figure 1a: Cumulative incidence of death due to bladder cancer, other 
cancer and other causes by smoking status (blue line=non-smoker, red line=current or ex-
smoker). 
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 Supplementary Figure 1b: Cumulative incidence of death due to bladder cancer, other 
cancer and other causes by risk of occupational exposure to bladder carcinogens (blue 
line=known or suspected risk of occupational exposure, red line=no increased risk of 
occupational exposure). 
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